PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response

Imaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology wa...

Full description

Bibliographic Details
Main Authors: Lingyi Sun, Zhonghan Li, Yongyong Ma, Johannes Ludwig, Hyun S. Kim, Dexing Zeng
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2021/6654262
id doaj-d9de2023ef1b489ca1e41309948bcffc
record_format Article
spelling doaj-d9de2023ef1b489ca1e41309948bcffc2021-06-21T02:24:24ZengHindawi LimitedBioMed Research International2314-61412021-01-01202110.1155/2021/6654262PET Imaging of CD8 via SMART for Monitoring the Immunotherapy ResponseLingyi Sun0Zhonghan Li1Yongyong Ma2Johannes Ludwig3Hyun S. Kim4Dexing Zeng5Center for Radiochemistry ResearchCenter for Radiochemistry ResearchCenter for Radiochemistry ResearchDepartment of Diagnostic and Interventional Radiology and NeuroradiologyDepartment of Radiology and Biomedical ImagingCenter for Radiochemistry ResearchImaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology was conducted. Mice bearing a subcutaneous colorectal CT26 tumor received three times different immunotherapy treatments (PD1 or CTLA4 or combined). On either day 7 or day 14 after the first time treatment, the PET imaging study was performed with sequentially administered TCO-modified anti-CD8 antibody and 64Cu-labeled MeTz-NOTA-RGD. However, no positive response was detected, probably due to (1) inappropriate selection of biomarkers for the SMART strategy, (2) limited TCO modification on the anti-CD8 antibody, and (3) inadequate response of the CT26 tumor to the selected immunotherapies. Therefore, the potential of applying SMART in imaging CD8 was not demonstrated in this study, and further optimization will be necessary before it can be applied in imaging CD8.http://dx.doi.org/10.1155/2021/6654262
collection DOAJ
language English
format Article
sources DOAJ
author Lingyi Sun
Zhonghan Li
Yongyong Ma
Johannes Ludwig
Hyun S. Kim
Dexing Zeng
spellingShingle Lingyi Sun
Zhonghan Li
Yongyong Ma
Johannes Ludwig
Hyun S. Kim
Dexing Zeng
PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
BioMed Research International
author_facet Lingyi Sun
Zhonghan Li
Yongyong Ma
Johannes Ludwig
Hyun S. Kim
Dexing Zeng
author_sort Lingyi Sun
title PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
title_short PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
title_full PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
title_fullStr PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
title_full_unstemmed PET Imaging of CD8 via SMART for Monitoring the Immunotherapy Response
title_sort pet imaging of cd8 via smart for monitoring the immunotherapy response
publisher Hindawi Limited
series BioMed Research International
issn 2314-6141
publishDate 2021-01-01
description Imaging of CD8 receptors on T-cells by positron emission tomography (PET) has been considered a promising strategy for monitoring the treatment response to immunotherapy. In this study, a trial of imaging CD8 with our newly developed sequential multiple-agent receptor targeting (SMART) technology was conducted. Mice bearing a subcutaneous colorectal CT26 tumor received three times different immunotherapy treatments (PD1 or CTLA4 or combined). On either day 7 or day 14 after the first time treatment, the PET imaging study was performed with sequentially administered TCO-modified anti-CD8 antibody and 64Cu-labeled MeTz-NOTA-RGD. However, no positive response was detected, probably due to (1) inappropriate selection of biomarkers for the SMART strategy, (2) limited TCO modification on the anti-CD8 antibody, and (3) inadequate response of the CT26 tumor to the selected immunotherapies. Therefore, the potential of applying SMART in imaging CD8 was not demonstrated in this study, and further optimization will be necessary before it can be applied in imaging CD8.
url http://dx.doi.org/10.1155/2021/6654262
work_keys_str_mv AT lingyisun petimagingofcd8viasmartformonitoringtheimmunotherapyresponse
AT zhonghanli petimagingofcd8viasmartformonitoringtheimmunotherapyresponse
AT yongyongma petimagingofcd8viasmartformonitoringtheimmunotherapyresponse
AT johannesludwig petimagingofcd8viasmartformonitoringtheimmunotherapyresponse
AT hyunskim petimagingofcd8viasmartformonitoringtheimmunotherapyresponse
AT dexingzeng petimagingofcd8viasmartformonitoringtheimmunotherapyresponse
_version_ 1721369415289667584